PSA+COVID-19: Connecting on Patient Care During a Pandemic

COVID-19 has made providing care to patients with psoriasis and psoriatic arthritis (PsA) more uncertain and complex. This 30-minute online activity is presented by the nationally and internationally recognized rheumatology expert who will review recommendations relevant to treatment of PsA by American College of Rheumatology, National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, and European League Against Rheumatism. The presenter also discusses how COVID-19 has impacted rheumatology community views on the use of biologic therapies. This activity features data and clinical scenarios that support and illustrate accurate evaluation of the benefit-to-risk ratio of immunosuppressive therapeutic interventions for PsA. It also covers treatment decisions about initiating, delaying, or stopping, PsA treatment with a conventional, targeted synthetic, or biologic disease-modifying antirheumatic drug (DMARD).   

Release Date: November 18, 2020
Valid Until: November 18, 2021

Activity
Materials

Faculty

Alvin F. Wells
Alvin F. Wells, MD, PhD, FACR  

Visiting Foreign Professor, Karolinska Institute, Stockholm, Sweden  
Director, Aurora Rheumatology and Immunotherapy Center;  
Adjunct Assistant Professor, Duke University Medical Center  
Assistant Clinical Professor, Medical College of Wisconsin

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Discuss

Review current treatment approaches using conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.

Apply

Summarize evolving recommendations and clinical practice guidelines related to COVID-19 that should be considered when providing care to patients with PsA.

Recognize

Explain scenarios in which it is appropriate to initiate, delay, or stop PsA treatment in relation to COVID-19. 

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.  

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:  

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD; Megan Ragan

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:   

Faculty Presenter: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer 
  • Contracted Research: AbbVie, Amgen, Eli Lilly

Activity Information

Target Audience
This activity is designed for rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs. 

Provider
This activity is provided by Forefront Collaborative.

Commercial Support 
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Open Registration